Luis, Today's announcement!
Wednesday August 19, 7:02 am Eastern Time
Company Press Release
Caprius Announces Major Upgrade
to Aurora System
Research Workstation Installed At Faulkner-Sagoff Centre
WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 19, 1998-- Caprius Inc.
(NASDAQ:CAPR - news) announced today the pre-production release of its Research
Workstation, a major upgrade to its Aurora(R) dedicated Breast MRI System, has been
completed and is being installed at the Faulkner-Sagoff Breast Imaging and Diagnostic Centre in
Boston.
The Research Workstation is a computer-based Digital Image Processing Tool that allows the
physicians to review Aurora's three-dimensional MRI digital images. The images are transferred
from the Aurora to the Workstation through the hospital's digital network system and can be
digitally enhanced to identify, visualize, measure and analyze regions of interest/suspicion. For
example, breast tissue can be displayed simultaneously in three views to help visualize the
three-dimensional nature of a possible tumor. The tumor can then be measured in all directions to
determine its extent and analyzed to measure the percent enhancement from the introduction of a
contrast agent.
Enrique Levy, President and COO, stated, ''We believe that the Research Workstation will be a
tremendous asset for the physicians and radiologists as it will provide them with the tools to fully
exploit Aurora's image data. This initial Workstation at Faulkner will provide important feedback
to us prior to its commercialization in 1999.''
Caprius Inc. is dedicated to the development and commercialization of the Aurora system, a
breast imaging system based on magnetic resonance imaging (MRI). The Aurora is the only
FDA-cleared, MRI-based, dedicated breast imaging system in the United States.
Safe Harbor Statement:
The statements made in this press release which are not historical fact are ''forward-looking
statements'' which are based upon current expectations that include a number of risks and
uncertainties. Factors that could cause actual results to differ materially from the forward-looking
statements include delays in product development, lack of market acceptance of technology,
technological innovations of competitors and changes in health care regulations, including
reimbursement programs.
Contact:
Caprius Inc., Fort Lee, N.J.
Beverly Tkaczenko or Jorge Clemente,
800/476-0569
More Quotes and News:
Caprius Inc (Nasdaq:CAPR - news)
Related News Categories: biotech, medical/pharmaceutical |
